Loading news...
Ten large-cap stocks posted steep weekly losses, driven by analyst downgrades, leadership headlines, and sector pressure across healthcare, tech, and precious metals.
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
There was no company-specific news out on Axon last week. Instead, a broader sell-off in high-priced SaaS stocks took down Axon as well.
AustralianSuper Pty Ltd boosted its holdings in shares of Axon Enterprise, Inc (NASDAQ: AXON) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,779 shares of the biotechnology company's stock after acquiring an additional 1,806 shares during
Axon Enterprise (AXON) concluded the recent trading session at $549.86, signifying a -9.89% move from its prior day's close.
I reiterate a Strong Buy on AppLovin, driven by Axon Ads' accelerating network effects and AI-powered self-serve platform expansion. Axon's rapid onboarding of e-commerce advertisers, with 50% weekly spend growth, signals a powerful new growth engine beyond gaming. Prospecting campaigns and AI-generated creatives address key advertiser needs, boosting incremental sales and lowering barriers for smaller clients.
Axon stock fell 4% in 2025, marking its first losing year in a decade. The company seemed to be a victim of its own success as the stock got significantly more expensive over the last ten years.
Baillie Gifford and Co. decreased its holdings in shares of Axon Enterprise, Inc (NASDAQ: AXON) by 1.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 126,479 shares of the biotechnology company's stock after selling 1,771 shares during the period. Baillie
Exploring Baillie Gifford (Trades, Portfolio)'s Fourth Quarter 2025 Investment Adjustments Baillie Gifford (Trades, Portfolio) recently submitted the 13F filin
Zacks.com users have recently been watching Axon (AXON) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Dilation Capital Management LP increased its stake in shares of Axon Enterprise, Inc (NASDAQ: AXON) by 64.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,596 shares of the biotechnology company's stock after buying an additional 2,989 shares during
Axon Enterprise (NASDAQ: AXON - Get Free Report) and Rheinmetall (OTCMKTS:RNMBY - Get Free Report) are both aerospace companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk and analyst recommendations. Analyst Ratings This is a breakdown of current ratings
Axon Enterprise (AXON) closed at $629.22 in the latest trading session, marking a -1.92% move from the prior day.
New York State Teachers Retirement System trimmed its stake in shares of Axon Enterprise, Inc (NASDAQ: AXON) by 1.9% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 62,616 shares of the biotechnology company's stock after selling 1,191 shares during the quarter. New
Axon (AXON) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Axon is reporting high growth and has a large market opportunity. It has a unique ecosystem of products with higher barriers to entry.
Applovin Corporation (NASDAQ: APP) stock climbed Wednesday as new data pointed to accelerating adoption of its Axon advertising platform.
Invesco Global Opportunities Fund outperformed most in consumer staples due to stock selection and in real estate due to an underweight allocation. Stock selection in consumer discretionary, IT and materials were the largest detractors from relative performance. An underweight in materials also detracted. Palantir Technologies' stock continued to trade well amid expectations for strong AI demand.
Axon remains a wide-moat, high-quality compounder with robust growth prospects despite a recent 35% pullback from highs. Short-term margin compression from tariffs and R&D spending is manageable; AXON raised full-year revenue guidance to $2.74B and reaffirmed 25% EBITDA margin. AXON's integrated AI-driven ecosystem, sticky software, and large proprietary datasets underpin its competitive advantage and long-term value creation.
Diversified Trust Co decreased its holdings in shares of Axon Enterprise, Inc (NASDAQ: AXON) by 11.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,189 shares of the biotechnology company's stock after selling 1,229 shares during the quarter. Diversified Trust Co's